108 related articles for article (PubMed ID: 28646023)
81. The S100 family is a prognostic biomarker and correlated with immune cell infiltration in pan-cancer.
Liang X; Huang X; Cai Z; Deng Y; Liu D; Hu J; Jin Z; Zhou X; Zhou H; Wang L
Discov Oncol; 2024 Apr; 15(1):137. PubMed ID: 38684596
[TBL] [Abstract][Full Text] [Related]
82. The Role of S100A6 in Human Diseases: Molecular Mechanisms and Therapeutic Potential.
Yang F; Ma J; Zhu D; Wang Z; Li Y; He X; Zhang G; Kang X
Biomolecules; 2023 Jul; 13(7):. PubMed ID: 37509175
[TBL] [Abstract][Full Text] [Related]
83. Deregulated calcium signaling in blood cancer: Underlying mechanisms and therapeutic potential.
Immanuel T; Li J; Green TN; Bogdanova A; Kalev-Zylinska ML
Front Oncol; 2022; 12():1010506. PubMed ID: 36330491
[TBL] [Abstract][Full Text] [Related]
84. The role of TBK1 in cancer pathogenesis and anticancer immunity.
Runde AP; Mack R; S J PB; Zhang J
J Exp Clin Cancer Res; 2022 Apr; 41(1):135. PubMed ID: 35395857
[TBL] [Abstract][Full Text] [Related]
85. Targeting TANK-binding kinase 1 (TBK1) in cancer.
Revach OY; Liu S; Jenkins RW
Expert Opin Ther Targets; 2020 Nov; 24(11):1065-1078. PubMed ID: 32962465
[TBL] [Abstract][Full Text] [Related]
86. TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis.
Zhu L; Li Y; Xie X; Zhou X; Gu M; Jie Z; Ko CJ; Gao T; Hernandez BE; Cheng X; Sun SC
Nat Cell Biol; 2019 Dec; 21(12):1604-1614. PubMed ID: 31792381
[TBL] [Abstract][Full Text] [Related]
87. S100 proteins as therapeutic targets.
Bresnick AR
Biophys Rev; 2018 Dec; 10(6):1617-1629. PubMed ID: 30382555
[TBL] [Abstract][Full Text] [Related]
88. S100 Proteins in Acute Myeloid Leukemia.
Brenner AK; Bruserud Ø
Neoplasia; 2018 Dec; 20(12):1175-1186. PubMed ID: 30366122
[TBL] [Abstract][Full Text] [Related]
89. S100A6 protein: functional roles.
Donato R; Sorci G; Giambanco I
Cell Mol Life Sci; 2017 Aug; 74(15):2749-2760. PubMed ID: 28417162
[TBL] [Abstract][Full Text] [Related]
90. Updates in the biology and therapy for infant acute lymphoblastic leukemia.
Guest EM; Stam RW
Curr Opin Pediatr; 2017 Feb; 29(1):20-26. PubMed ID: 27841777
[TBL] [Abstract][Full Text] [Related]
91. Amlexanox Downregulates S100A6 to Sensitize
Tamai H; Yamaguchi H; Miyake K; Takatori M; Kitano T; Yamanaka S; Yui S; Fukunaga K; Nakayama K; Inokuchi K
Cancer Res; 2017 Aug; 77(16):4426-4433. PubMed ID: 28646023
[TBL] [Abstract][Full Text] [Related]
92. Inhibition of S100A6 induces GVL effects in MLL/AF4-positive ALL in human PBMC-SCID mice.
Tamai H; Miyake K; Yamaguchi H; Shimada T; Dan K; Inokuchi K
Bone Marrow Transplant; 2014 May; 49(5):699-703. PubMed ID: 24583627
[TBL] [Abstract][Full Text] [Related]
93. Resistance of MLL-AFF1-positive acute lymphoblastic leukemia to tumor necrosis factor-alpha is mediated by S100A6 upregulation.
Tamai H; Miyake K; Yamaguchi H; Takatori M; Dan K; Inokuchi K; Shimada T
Blood Cancer J; 2011 Nov; 1(11):e38. PubMed ID: 22829076
[TBL] [Abstract][Full Text] [Related]
94. HMGA2 as a potential molecular target in KMT2A-AFF1-positive infant acute lymphoblastic leukaemia.
Wu Z; Eguchi-Ishimae M; Yagi C; Iwabuki H; Gao W; Tauchi H; Inukai T; Sugita K; Ishii E; Eguchi M
Br J Haematol; 2015 Dec; 171(5):818-29. PubMed ID: 26403224
[TBL] [Abstract][Full Text] [Related]
95. Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion.
Tretti Parenzan C; Molin AD; Longo G; Gaffo E; Buratin A; Cani A; Boldrin E; Serafin V; Guglielmelli P; Vannucchi AM; Cazzaniga G; Biondi A; Locatelli F; Meyer LH; Buldini B; Te Kronnie G; Bresolin S; Bortoluzzi S
Blood Adv; 2024 Mar; 8(5):1305-1319. PubMed ID: 38029383
[TBL] [Abstract][Full Text] [Related]
96.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
97.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
98.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
99.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
